Yosuke Togashi
Overview
Explore the profile of Yosuke Togashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
4767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuura H, Ishino T, Ninomiya T, Ninomiya K, Tachibana K, Honobe-Tabuchi A, et al.
Cancer Sci
. 2025 Feb;
PMID: 40017103
Regulatory T (T) cells have an immunosuppressive function, and programmed death-1 (PD-1)-expressing T cells reportedly induce resistance to PD-1 blockade therapies through their reactivation. However, the effects of antigenicity on...
2.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, et al.
Nature
. 2025 Feb;
639(8053):E5.
PMID: 39948434
No abstract available.
3.
Nishi T, Morita A, Hara N, Makimoto G, Ninomiya K, Fujii M, et al.
Lung Cancer
. 2025 Feb;
201:108415.
PMID: 39922174
Background: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are highly effective in treating ALK-rearranged non-small-cell lung cancer (NSCLC). However, at least 40% of patients develop acquired resistance during treatment....
4.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, et al.
Nature
. 2025 Jan;
638(8049):225-236.
PMID: 39843734
Cancer cells in the tumour microenvironment use various mechanisms to evade the immune system, particularly T cell attack. For example, metabolic reprogramming in the tumour microenvironment and mitochondrial dysfunction in...
5.
Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, et al.
Cancer Res
. 2025 Jan;
85(6):1082-1096.
PMID: 39804971
Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti-PD-1 mAb or anti-CTLA4 mAb seems to be less effective...
6.
Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, et al.
Cancer Res Commun
. 2024 Dec;
5(1):84-93.
PMID: 39679910
This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that...
7.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):273-285.
PMID: 39602577
Regulatory T (Treg) cells play key roles in cancer immunity by suppressing a range of antitumor immune responses and contributing to resistance to PD-1 blockade therapy. Given their critical roles...
8.
Nakajima T, Kanno T, Ueda Y, Miyako K, Endo T, Yoshida S, et al.
Cell Mol Immunol
. 2024 Oct;
21(11):1350.
PMID: 39379605
No abstract available.
9.
Nakajima T, Kanno T, Ueda Y, Miyako K, Endo T, Yoshida S, et al.
Cell Mol Immunol
. 2024 Aug;
21(11):1266-1281.
PMID: 39187636
T helper 9 (Th9) cells are interleukin 9 (IL-9)-producing cells that have diverse functions ranging from antitumor immune responses to allergic inflammation. Th9 cells differentiate from naïve CD4 T cells...
10.
Mukohara F, Iwata K, Ishino T, Inozume T, Nagasaki J, Ueda Y, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(35):e2320189121.
PMID: 39167601
Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8 T cells that can expand and directly attack cancer cells (cancer-specific T cells) among...